RecruitingPhase 2NCT03875638

Treating Hyperexcitability in AD With Levetiracetam

Studying Early-onset autosomal dominant Alzheimer disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Beth Israel Deaconess Medical Center
Intervention
Levetiracetam(drug)
Enrollment
85 target
Eligibility
50-90 years · All sexes
Timeline
20192025

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03875638 on ClinicalTrials.gov

Other trials for Early-onset autosomal dominant Alzheimer disease

Additional recruiting or active studies for the same condition.

See all trials for Early-onset autosomal dominant Alzheimer disease

← Back to all trials